A multinational, prospective, open-label, roll-over study (LIBERTY) to provide post-trial access to treatment for patients with severe haemophilia A who have completed a previous trial with efanesoctocog alfa.
Datos básicos
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
SWEDISH ORPHAN BIOVITRUM AB
Cita
A multinational, prospective, open-label, roll-over study (LIBERTY) to provide post-trial access to treatment for patients with severe haemophilia A who have completed a previous trial with efanesoctocog alfa. (Sobi.BIVV001-002). SWEDISH ORPHAN BIOVITRUM AB. 2024-2026. IP:SATURNINO HAYA GUAITA.
Portal de investigación